Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation-Reference-Cited by-同舟云学术

Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation

Published:2016-08-22 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Desborough Michael¹,Estcourt Lise J¹,Doree Carolyn²,Trivella Marialena³,Hopewell Sally⁴,Stanworth Simon J⁵,Murphy Michael F⁶

Affiliation:

1. NHS Blood and Transplant; Haematology/Transfusion Medicine; Oxford UK

2. NHS Blood and Transplant; Systematic Review Initiative; John Radcliffe Hospital Oxford UK OX3 9BQ

3. University of Oxford; Centre for Statistics in Medicine; Botnar Research Centre Windmill Road Oxford UK OX3 7LD

4. University of Oxford; Oxford Clinical Trials Research Unit; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Windmill Road Oxford Oxfordshire UK OX3 7LD

5. Oxford University Hospitals NHS Foundation Trust and University of Oxford; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; John Radcliffe Hospital, Headley Way Headington Oxford UK OX3 9BQ

6. Oxford University Hospitals NHS Foundation Trust and University of Oxford; NHS Blood and Transplant; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; John Radcliffe Hospital Headington Oxford UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference247 articles.

1. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia;Archimbaud;Blood,1999

2. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia;Archimbaud;Blood,1999

3. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - a randomized, placebo-controlled, double-blind safety and efficacy study;Geissler;Annals of Hematology,2003

4. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - a randomized, placebo-controlled, double-blind safety and efficacy study;Geissler;Annals of Hematology,2003

5. A compare study on human recombinant thrombopoietin (TPIAO) promote platelet recovery in haploidentical hematopoietic stem cell transplantation recipients Chinese clinical trial registry number: ChiCTR-TRC-11001774

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Safety of Endoscopic Procedures in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis;Cureus;2024-01-06

2. Are Cervical Pessaries Effective in Preventing Preterm Birth?;Cureus;2024-01-06

3. Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review;PharmacoEconomics;2023-05-05

4. Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia;Expert Review of Hematology;2023-04-14

5. Promotion of Platelet Production by Co-Transplantation of Mesenchymal Stem Cells in Bone Marrow Transplantation;Tissue Engineering and Regenerative Medicine;2022-01-11